2025 has seen a wave of A-share companies pursuing H-share listings in Hong Kong, but FORMS SYNTRON's Hong Kong IPO process came to an abrupt halt at the pricing stage. According to the prospectus, the company planned to globally offer 58.96 million H-shares at a maximum offer price of HK$16 per share, targeting a fundraising ceiling of approximately HK$940 million, with joint sponsors CMB International and Guosen Securities (Hong Kong) and a planned listing date of September 22. On September 19, FORMS SYNTRON announced the suspension of the offering, attributing the decision to "considering multiple factors (including current market conditions)," and stated that all application monies would be fully refunded. The company also emphasized that the delay decision would not affect current operations, and that the company and joint coordinators are carefully evaluating the updated timeline for listing.
However, this IPO that hit the "pause button" at the last moment of the offering period reflects far more than just "market conditions" - the insufficient AH discount level, limited coverage capabilities of the underwriting team, and the company's lack of preparation for real pricing feedback are the core reasons behind this shelved listing.
Insufficient Offering Discount Compared to Market Consensus Becomes Direct Trigger for Suspension
Looking at recent A+H pricing patterns, using Hong Kong IPO projects with valuation ranges between 10 billion and 30 billion RMB that have proceeded since the start of 2025 as benchmarks, similar targets typically offer H-share prices at approximately 60% discount to their A-share closing prices. In contrast, FORMS SYNTRON's H-share offering at the maximum HK$16 per share represents only a 37.6% discount to its A-share price, significantly below market norms for the same period. Furthermore, during the offering window, the company's A-share price weakened, further narrowing the potential offering discount from 40.0% to 37.6%. By comparison, Transwarp Technology, which pursued its IPO during the same period, set its offering price range at HK$49 to HK$61, ultimately pricing at the HK$49 floor - a discount of approximately 59.9% to its A-share price. Even so, Transwarp Technology closed below its offer price on its September 21 debut, with the H-share discount to A-shares widening further to 65.8%. Notably, Transwarp Technology's A-share price trended modestly upward during its offering period, with the discount expanding slightly from 57.5% to 59.9%, which increased the safety margin for investors.
The difference between the two cases demonstrates that beyond the setting of the offering price range, volatility in the A-share secondary market directly impacts the pricing space for A+H offerings. Notably, FORMS SYNTRON did not set a minimum offer price during this offering. If the company had been willing, it could have priced the offering lower to satisfy the 60% or even greater discount level, thereby completing its Hong Kong listing and avoiding the suspension. But the company and underwriting syndicate ultimately chose to halt the offering. The question follows: why choose suspension over accepting a lower price?
Inexperienced Sponsor Team and Lack of Early Pricing Feedback Amplify Expectation Mismatch
Behind the offering suspension lies the strong likelihood that the company was not prepared to accept a lower discount, a result that also reflects deficiencies in the sponsors' early pricing predictions. The joint sponsors for this Hong Kong IPO were CMB International and Guosen Securities (Hong Kong). Among A+H projects since 2025, CMB International has participated as sponsor in only two similar projects, both of which were smaller in scale than FORMS SYNTRON's offering. Guosen Securities (Hong Kong) has no prior record as sponsor for A+H projects, reflecting the relatively limited experience of these two investment banks in cross-border A+H underwriting in the Hong Kong market.
Further examination shows that both projects involving CMB International were jointly underwritten with top-tier investment banks - one with Huatai and Deutsche Bank, the other with CICC. In structures where stronger investment banks took the lead, CMB International played more of a supporting role. Additionally, both of those offerings were completed in the first half of 2025, when market conditions differed significantly from the current environment. In the FORMS SYNTRON project, without the backing of a leading investment bank, the lack of A+H experience was amplified considerably. On one hand, the sponsor team may not have covered enough institutional investors - particularly in the Hong Kong market, where covering such investors requires long-term relationship building and professional cross-border capital market communication capabilities. On the other hand, even where investor coverage was achieved, the sponsor team may not have obtained genuinely truthful discount feedback - institutional investors may hold back when dealing with unfamiliar smaller investment banks, declining to reveal their true price expectations. By the time the offering period ended, the real market feedback surfaced, but there was no longer time to conduct sufficient re-pricing communication. The company could not accept a discount level that had not been adequately anticipated in advance, ultimately forcing the suspension of the offering.
Core Constraint for Relaunch: The Company's Acceptance of Its Valuation
After shelving the listing, FORMS SYNTRON faces a core question: whether it can restart, and when. There are indeed many cases in the market where companies resumed after suspending their listings, with varying timelines - some restart quickly, others take months or even longer, with constraints differing by company. But if the suspension resulted from valuation or discount-related pricing issues, the most critical variable is whether the company can ultimately accept a price reduction.
Looking at historical cases, BlietHy-Tian (ASX: BHT) serves as a typical reference point. After launching its offering in November 2025, the company failed to complete its issuance due to insufficient pricing discounts - its offer price range of HK$347.5 to HK$389 represented only a 1.8% to 12.2% discount to its A-share price, far below the discount conventions prevailing in the Hong Kong market at the time - and the original approval lapsed before its validity period expired. In August 2026, BlietHy-Tian filed its prospectus for the fourth time while simultaneously changing its sponsor team - Goldman Sachs and JPMorgan exited, with Jefferies, CICC, and Deutsche Bank brought in, with market speculation attributing the change to unresolved disagreements over offering discounts. From filing to approval lapse and re-filing, the entire process took over a year, demonstrating that resolving valuation disagreements requires time and concessions from both parties, and cannot be bridged within a short period.
On September 22, Junxin Co (ASX: JXH) also issued a similar announcement, stating that "in light of current market conditions, after careful evaluation and consultation with joint sponsors and joint global coordinators, the company has decided to determine the matters related to the H-share issuance and listing based on market changes." This also reflects to a certain extent that pricing disagreements are becoming an increasingly common "roadblock" for A-share companies seeking listings in Hong Kong.
For FORMS SYNTRON, whether its Hong Kong IPO can be restarted depends first on whether the company can adjust its valuation expectations to align with Hong Kong market pricing logic, and only secondarily on procedural matters such as application processes and document updates. This choice, in turn, depends on how urgent the company's practical need to access the Hong Kong market truly is.
Financing Needs May Not Be Urgent: Ample Cash Reserves and Business Concepts Cannot Offset AH Valuation Differences
Examining the company's financial data, FORMS SYNTRON's urgency to raise funds through a Hong Kong listing is not particularly pressing. As of the end of June 2026, the company held cash balances of RMB 990 million, total assets of RMB 1.73 billion, and a debt-to-asset ratio of only 4.7%, with virtually no interest-bearing debt pressure. Shareholders' equity stood at RMB 1.65 billion, reflecting a stable overall financial structure. On the profitability front, the company's performance shows periodic fluctuations. In 2025, total operating revenue reached RMB 630 million, down 14.8% year-on-year, while net profit attributable to parent shareholders was RMB 70 million, up 10.3% year-on-year. In the first half of 2026, total operating revenue was RMB 350 million, up 14.9% year-on-year, while net profit attributable to parent shareholders was RMB 40 million, down 17.3% year-on-year. Operating cash flow in the first half of 2026 was RMB 30 million, with net cash decrease of RMB 90 million - cash flow has marginally weakened, but has not yet created rigid external financing pressure.
However, the "stablecoin concept" is a card the company holds. FORMS SYNTRON's FINNOSafe platform supports technical services for stablecoin issuance, distribution, and payment processes, and the company has provided consulting services to multiple stablecoin issuer applicants. Following the Hong Kong Monetary Authority's issuance of stablecoin issuer licenses, FORMS SYNTRON has been viewed by the market as a potential beneficiary - Hong Kong investors may show greater acceptance of such targets. But concepts cannot substitute for pricing. A+H projects carry inherent discount requirements, and this is even more pronounced for smaller companies. FORMS SYNTRON falls into the small-to-mid-cap category within Hong Kong institutional investor frameworks, lacking sufficient bargaining power. The so-called "good concept plus small size" often means that larger discounts are required to compensate for liquidity risk.
Conclusion
The suspension of FORMS SYNTRON's Hong Kong IPO is fundamentally a failure of market expectation management. The underwriting team failed to adequately communicate true market pricing signals in the early stages, leaving the company to confront discount requirements far removed from its own expectations at the pricing stage. Meanwhile, the company's ample cash reserves and possession of a scarce business concept further reduced its willingness to issue at a discount. If the company still plans to pursue an H-share listing in the future, procedural prospectus updates are merely foundational - the real test lies in whether the company can confront the valuation system differences of the A+H market and accept the pricing results that the Hong Kong market delivers.
Comments